Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Study of ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Progressed on Androgen Receptor (AR) Pathway Inhibition

NCT05682443 is registered in ClinicalTrials.gov with OncoC4, Inc. as lead sponsor.

NCT NCT05682443
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05682443 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Study of ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Progressed on Androgen Receptor (AR) Pathway Inhibition
Lead sponsor
OncoC4, Inc.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
December 11, 2023
Completion date
November 30, 2027
Enrollment
148 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic castration-resistant prostate cancer